Phone : 1-415-349-0054 Toll Free : 1-888-202-9519 Email : sales @ radiantinsights . com Web : http :// www . radiantinsights . com /
Respiratory Drugs Market Research Report 2022
Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies , with Asthma and Cystic Fibrosis Leading the Way
Summary The respiratory therapy area consists of indications that affect the respiratory system in different ways , such as the scarring of lung tissue , and excessive production of mucus in the airways , thereby decreasing lung function . Some of the key indications in this therapy area include asthma , chronic obstructive pulmonary disease ( COPD ), cystic fibrosis ( CF ) and idiopathic pulmonary fibrosis ( IPF ). The causes of respiratory disorders vary significantly across each indication , and include factors such as environment , occupation , genetic predisposition and aging .
The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms , rather than the cause . This means that treatment options can be diverse in terms of their targets and mechanisms of action . This is most notable in CF , where patients may be prescribed a combination of drugs from several treatment categories , including mucolytic agents , bronchodilators and antibiotics . The COPD and asthma treatment landscapes employ similar symptomatic treatments , including bronchodilators and inhaled corticosteroids .
Browse Full Research Report @: http :// www . radiantinsights . com / research / globalrespiratory-drugs-market-to-2022
However , over the past decade the treatment of respiratory disorders has developed significantly , as has the importance for novel therapies and targeted therapies . The approval of the products Orkambi and Kalydeco , in 2014 and 2012 respectively , gave patients disease-modifying treatment options for CF . Another important entry was the first biologic drug - omalizumab - approved in 2014 for the treatment of severe asthma . The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala ( mepolizumab ) in November 2015 .
Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline , the pipeline also contains promising targeted biologic therapies , which reflects their growing prominence in this therapy area . Overall , 908 products are currently in active in development for respiratory disorders .
Scope The respiratory disorders market is characterized by entrenched , commercially successful therapies . � Which classes of drug dominate the market ?
https :// www . facebook . com / RadiantInsights
https :// www . linkedin . com / company / radiant-insights https :// twitter . com / radiantinsights
https :// plus . google . com /+ Radiantinsights